The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKibo Energy Regulatory News (KIBO)

Share Price Information for Kibo Energy (KIBO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.0375
Bid: 0.035
Ask: 0.04
Change: 0.00 (0.00%)
Spread: 0.005 (14.286%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.0375
KIBO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Kibo Subsidiary Announces Business Update

26 Apr 2024 07:00

RNS Number : 0970M
Kibo Energy PLC
26 April 2024
 

Kibo Energy PLC (Incorporated in Ireland)

(Registration Number: 451931)

(External registration number: 2011/007371/10)

LEI Code: 635400WTCRIZB6TVGZ23

Share code on the JSE Limited: KBO

Share code on the AIM: KIBO

ISIN: IE00B97C0C31

('Kibo' or 'the Company')

 

Dated: 26 April 2024

 

Kibo Energy PLC ('Kibo' or the 'Company')

 

Kibo Subsidiary Announces Business Update

 

Kibo Energy PLC (AIM: KIBO; AltX: KBO), the renewable energy-focused development company, announces a business update by its subsidiary Mast Energy Developments PLC ('MED'), a UK-based multi-asset owner, developer and operator in the rapidly growing flexible power market.

 

Further details can be found in the full MED RNS Announcement, which is available below and at med.energy.

 

-------------------------

 

Dated: 26 April 2024

 

Mast Energy Developments PLC ('MED' or 'the Company')

 

Business Update

 

Mast Energy Developments PLC, the UK-based multi-asset owner, developer and operator in the rapidly growing flexible power market, is pleased to announce an update regarding business operational matters.

 

Pyebridge

 

Further to the Company's previous RNS announcement dated 11 April 2024, MED has now received official confirmation that its Pyebridge 9MW flexible power generation asset ("Pyebridge") has passed its Satisfactory Performance Days ("SPD") requirements under its current existing T-1 Capacity Market contract (the "CM Contract"). This means that Pyebridge will retain the current CM Contract's associated annual gross profit margin income of c. £308,000 which is paid and received monthly in arrears.

 

In addition to the current CM Contract, as previously announced MED's Pyebridge site has secured further Capacity Market contracts to ensure minimum annual gross profit margin income totaling c. £817,000 until 2028. The Pyebridge site's Capacity Market contracts' gross profit margin income payments are in addition to its electricity generation trading revenue via its PPA with Statkraft.

 

Further, following the recent successful completion of the first phase of the Pyebridge work programme, the final preparations for the next larger second phase (the "2nd Phase") are near complete, and implementation is expected shortly. The 2nd Phase will be performed in separate consecutive tranches on each of the Pyebridge site's 3x gensets, and is expected to take around 6 to 8 weeks per genset. The completion of each of the three consecutive tranches of the 2nd Phase will result in each of the 3x gensets operating and generating at its full expected availability, efficiency, revenue generation and profitability potential.

 

The MED management team is working closely with RiverFort regarding the implementation of the 2nd Phase which will be funded under the new Funding Agreement (see RNS dated 28 February 2024 for further details). MED appreciates the ongoing support that RiverFort provides to the Company and Pyebridge.

 

Pieter Krügel, MED CEO, commented"We are pleased that our Pyebridge asset has successfully passed its SPD requirements, resulting in the retention of its current CM Contract's associated annual gross profit margin income of c. £308,000. The next step in the process at Pyebridge is to kick off the 2nd Phase of the work programme, which is expected shortly. We are looking forward to updating the market with progress in due course."

 

ENDS

 

This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ('UK MAR'). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

For further information please visit www.med.energy or contact:

Pieter Krügel

info@med.energy

Mast Energy Developments PLC

CEO

Jon Belliss

+44 (0)20 7399 9425

Novum Securities

Corporate Broker

 

_________________________

 

**ENDS**

 

For further information please visit www.kibo.energy or contact:

 

Louis Coetzee

info@kibo.energy

Kibo Energy PLC

Chief Executive Officer

James Biddle Roland Cornish

+44 207 628 3396

Beaumont Cornish Limited

Nominated Adviser

Claire Noyce

+44 20 3764 2341

Hybridan LLP

Joint Broker

Damon Heath

+44 207 186 9952

Shard Capital Partners LLP

Joint Broker

 

Beaumont Cornish Limited ('Beaumont Cornish') is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

 

Johannesburg

26 April 2024

Corporate and Designated Adviser

River Group

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBUGDSSBDDGSU
Date   Source Headline
30th Apr 20247:00 amRNSKibo Subsidiary MED Accounts’ Publication
26th Apr 20247:00 amRNSKibo Subsidiary Announces Business Update
23rd Apr 20242:30 pmRNSKibo Subsidiary Announces Major Shareholdings
11th Apr 20247:00 amRNSKibo Subsidiary MAST Announces Business Update
5th Mar 20247:00 amRNSIssue of Shares to Service Provider
4th Mar 202410:45 amRNSKibo Subsidiary Announces TR-1 Notification
28th Feb 20247:00 amRNSMAST New Funding Partner & Proventure Cancellation
21st Feb 20242:46 pmRNSHolding(s) in Company
20th Feb 20241:00 pmRNSKibo Subsidiary Announces TR-1 Notification
9th Feb 202412:45 pmRNSResults of Extraordinary General Meeting
5th Feb 20241:55 pmRNSKibo Subsidiary MAST Announces TR-1 Notification
31st Jan 202410:48 amRNSDirector/PDMR Shareholding
24th Jan 20243:45 pmRNSKibo Subsidiary MAST Announces TR-1 Notification
19th Jan 20241:52 pmRNSPDMR Share Sale
18th Jan 20247:00 amRNSNotice of Extraordinary General Meeting (“EGM”)
16th Jan 202410:50 amRNSCorrection on MED Shareholding
16th Jan 20247:00 amRNSKibo Strategy Update
11th Jan 20247:00 amRNSConversion, Equity Issue, TVR & Board Changes
8th Jan 20247:00 amRNSKibo Subsidiary Announces an Update on JVA
2nd Jan 20247:00 amRNSKibo Subsidiary - Further Update of Payment to JVA
22nd Dec 20237:00 amRNSKibo Subsidiary Announces JVA Completion Update
19th Dec 20232:00 pmRNSPDMR Share Sale
15th Dec 20237:00 amRNSSubsidiary Director Loan & PMDR Share Sale
11th Dec 20238:21 amRNSKibo Subsidiary Update JVA Completion Announcement
11th Dec 20237:00 amRNSMAST: Further Update to the Completion of JVA
7th Dec 20232:15 pmRNSResult of AGM
1st Dec 20237:00 amRNSKibo Subsidiary Announces Update of JVA
15th Nov 20237:00 amRNSNotice of AGM
13th Nov 20237:00 amRNSKibo UK Subsidiary JVA Interim Payment Update
26th Oct 20237:00 amRNSChange of Holding in Mast Energy Developments PLC
23rd Oct 20237:00 amRNSKibo Subsidiary - Update on the Completion of JVA
5th Oct 20237:00 amRNSPartial Settlement of Outstanding Shareholder Loan
4th Oct 20237:00 amRNSSale of Coal Interest in Botswana Power Project
29th Sep 20237:00 amRNSUnaudited Interim Results
22nd Sep 20237:00 amRNSKibo Subsidiary Announces Update on JVA Completion
1st Sep 20237:00 amRNSKibo Subsidiary Announces Further Update on JVA
25th Aug 20237:00 amRNSKibo Subsidiary MED Unaudited Interim Results
16th Aug 202310:10 amRNSClarification on Inaccurate Moneyweb Article
7th Aug 202310:25 amRNSDirector/PDMR Shareholding
4th Aug 20237:00 amRNSKibo Subsidiary Announces Update on JV Completion
31st Jul 20237:00 amRNSUpdate on MED Definitive and Binding JVA
24th Jul 20234:40 pmRNSTR-1: Notification of major holdings
12th Jul 20231:15 pmRNSKibo Subsidiary Announces Definitive & Binding JVA
3rd Jul 20237:00 amRNSOperational Update: Q2 2023
29th Jun 20237:00 amRNSAnnual Financial Report
16th Jun 20233:51 pmRNSHolding(s) in Company
2nd Jun 20232:30 pmRNSResults of EGM
26th May 202312:15 pmRNSWarrant Exercise
23rd May 20232:30 pmRNSKibo Subsidiary MED Issue of Shares
22nd May 20233:00 pmRNSKibo Subsidiary Issue of Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.